Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis

• DOI: 10.3389/fcell.2021.639596
• Publication Date: 2021-05-24T06:25:14Z
• Authors: Haizhou Liu; Zihan Zhang; Yi Huang; Wene Wei; Shufang Ning; Jilin Li; Xinqiang Liang; Kaisheng Liu; Litu Zhang
• Keywords: Nomogram; Concordance

We aimed to develop and validate a comprehensive nomogram containing pre-treatment plasma HSP90AA1 predict the risk of breast cancer onset metastasis.We assessed expression HSP90s in patients using an online database. To verify results, 677 diagnosed with 146 benign disease between 2014 2019 were selected from our hospital divided into metastasis cohorts. focused on elucidate risks cohorts.Expression levels HSP90AA1, HSP90AA2, HSP90AB1, HSP90B1, TRAP1 linked progression. Survival analysis GEPIA OncoLnc databases indicated that upregulation HSP90AB1 was related poor overall survival. In cohort, carcinoembryonic antigen (CEA), carbohydrate 153 (CA153), T cells%, natural killer B neutrophil count, monocyte d-dimer incorporated nomogram. A high Harrell's concordance index (C-index) value 0.771 [95% confidence interval (CI), 0.725-0.817] could still be reached validation. predictors contained prediction included use CEA, CA153, 125 (CA125), platelet d-dimer. The C-index 0.844 (95% CI, 0.801-0.887) it well-calibrated. raised net clinical benefit range thresholds (5-92%) (1-90%).Our study revealed pretreatment combined other markers conveniently metastasis.